文献速递神经肿瘤

IDH突变型星形细胞瘤预后综合预测分析

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.
PubMed 文献 · Neuro Oncol · 2026-01-01

该研究纳入2005至2023年间210例新诊断WHO 2-4级IDH突变型星形细胞瘤患者,综合评估临床、分子、影像及手术因素对无进展生存期(PFS)的预测价值。中位PFS为106.8个月,5年PFS率67.5%。多变量分析显示较高初始KPS为有利预测因素,而较高WHO分级(主要驱动于4级)、较大总肿瘤体积及较小切除程度为不利预测因素。

要点

  • WHO 4级是IDH突变型星形细胞瘤不良预后的主要驱动因素。
  • 总肿瘤体积较大与切除程度较低均与PFS缩短独立相关。
  • 年龄和MGMT启动子甲基化在本队列中未显示显著预后价值。

核心结论

  • WHO 4级、总肿瘤体积和切除程度是IDH突变型星形细胞瘤PFS的重要预后因素。

研究设计与样本

  • 回顾性纳入2005至2023年间210例新诊断WHO 2-4级IDH突变型星形细胞瘤患者,评估临床、分子、影像及手术因素。
  • 通过自动容积分割量化总肿瘤体积、强化体积、非强化体积和坏死体积(cm3)。
  • 采用单变量和多变量Cox分析识别PFS的显著预测因素。

主要发现

  • 中位PFS为106.8个月,5年PFS率为67.5%。
  • 多变量分析中较高初始KPS为PFS有利预测因素(HR=0.76,P=.029)。
  • 较高WHO分级为不利预测因素(4级HR=2.91,P=.013;3级HR=1.01,P=.997;参照2级,总体P=.032),不良影响主要驱动于4级。
  • 较大总肿瘤体积为不利预测因素(HR=1.03,P=.013)。
  • 较小切除程度为不利预测因素(次全切除HR=1.80,P=.043;部分切除HR=2.14,P=.014;活检HR=3.79,P=.008;参照全切除,总体P=.015)。

关键数值与推荐

  • 年龄和MGMT启动子甲基化在本分析中未显示为显著预测因素。

临床怎么用

  • 对于IDH突变型星形细胞瘤患者,应关注WHO分级、总肿瘤体积和切除程度以辅助预后评估。
  • 在临床决策中,较高KPS提示较好预后,而4级、较大体积和较小切除范围提示较差预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To comprehensively investigate clinical, molecular, radiological, and surgical factors for prediction of progression-free survival (PFS) in patients with isocitrate dehydrogenase (IDH)-mutant astrocytomas. METHODS: A total of 210 patients with newly diagnosed World Health Organization (WHO) grade 2-4 IDH-mutant astrocytomas between 2005 and 2023 were included. Clinical, molecular, radiological, and surgical factors were evaluated. Total, contrast-enhancing, nonenhancing, and necrotic tumor volumes were quantified via automatic volumetric segmentation (cm3). Significant predictors of PFS were identified using univariable and multivariable Cox analyses. RESULTS: The median PFS was 106.8 months, with a 5-year PFS rate of 67.5%. On multivariable analysis, higher initial KPS (hazard ratio [HR] =0.76, P = .029) remained as a favorable predictor of PFS, while higher WHO grade (grade 3, HR = 1.01, P = .997; grade 4, HR = 2.91, P = .013; reference standard as grade 2, overall P = .032), larger total tumor volume (HR = 1.03, P = .013), and lesser extent of resection (EOR) (subtotal resection, HR = 1.80, P = .043; partial resection, HR = 2.14, P = .014; biopsy, HR = 3.79, P = .008; reference standard as gross total resection, overall P = .015) remained as unfavorable predictors of PFS. Age and O6-methylguanine-DNA methyltransferase promoter methylation were not significant predictors, while the adverse prognostic impact of WHO grade was primarily driven by WHO grade 4 tumors. CONCLUSIONS: Our work presents a detailed analysis of a large series of IDH-mutant astrocytomas, underscoring the prognostic importance of WHO grade 4, tumor volume, and EOR. People with brain tumors survive varying amounts of time, but we do not know why. We sought to improve our understanding of this issue by analyzing a large group of patients with a specific type of brain tumor, isocitrate dehydrogenase-mutant astrocytomas, for which we have detailed information on tumor type, World Health Organization tumor grade, and the time to tumor progression. We found that patients with grade 4 tumors did poorly, whereas patients with grade 2 or 3 tumors had longer survival. Total tumor volume and the percentage of tumor surgically removed helped predict outcome, but age and O6-methylguanine-DNA methyltransferase promoter methylation did not. These results improve our ability to predict survival and may help improve the treatment of patients with brain tumors.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Cho M, Kim M, Kim H, et al. A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients. Neuro Oncol. 2026. PMID: 42080952. doi:10.1093/neuonc/noag096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。